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Abstract
The almost universal belief that cancer is caused by mutation may gradually be giving way to the
belief that cancer begins as a cellular adaptation that involves the local epigenetic silencing of various
genes. In my own interpretation of the new epigenetic paradigm, the genes epigenetically
suppressed are genes that normally serve in post-embryonic life to suppress and keep suppressed
those other genes upon which embryonic development depends. Those other genes, if not silenced
or suppressed in the post-embryonic animal, become, I suggest, the oncogenes that are the basis
of neoplasia.
Mutations that occur in silenced genes supposedly go unrepaired and are, therefore, postulated to
accumulate, but such mutations probably play little or no causative role in neoplasia because they
occur in already epigenetically silenced genes. These mutations probably often serve to make the
silencing, and therefore the cancer, epigenetically irreversible.
The present paradigm
For the past half century, most cancer investigators have
thought, beyond any reasonable doubt, that each cancer
has its origin in a single cell that undergoes mutations to
give that cell a cancer phenotype or at least to set that cell
and its progeny on the path to forming an overt cancer [1].
This paradigm has been fostered by the ever increasing
awareness that cancers often harbor large numbers of
mutant genes and chromosomal abnormalities and that
many carcinogens are mutagens. The presence of large
numbers of mutations has led to the hypothesis that can-
cers may often progress because they contain a mutator
phenotype [2].
There is seemingly convincing evidence that many cancers
are of clonal origin, ie., they apparently develop from a
single cellular progenitor [3], a fact suggestive of a muta-
tional origin. It is also true that certain hereditary cancers
are associated with particular mutant genes. For example,
In the rare disease xeroderma pigmentosum, the inherited
genetic aberration increases susceptibility to UV-induced
mutagenesis and to skin cancer by as much as 1000 fold
[4]. This increase in tumor incidence, consequent upon a
particular inherited background genotype, is not really
relevant to the question of whether or not mutation is the
"cause" of cancer. The background genotype obviously
plays a great role in determining the frequency with which
cancer emerges, but for our purposes the cause is whatever
it is that determines which particular cell or group of cells,
among the many of the same genotype, shall proliferate to
form a neoplasm.
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The need for a new paradigm
A few observers have persisted in pointing out that there
are certain facts that are difficult to reconcile with the cur-
rent mutational paradigm [1,5-9]. None of the arguments
is conclusive- there would be no debate if that were the
case- but in aggregate they do make a strong case for ques-
tioning the prevalent paradigm.
One observation that suggests that the mutation paradigm
might be wrong is the fact that, among chemical carcino-
gens, some fifty percent of those examined were, at least
within the sensitivity limits of the test (Ames test), seem-
ingly non-mutagenic, at least in E. coli [10]; more impor-
tantly, although there is some correlation between the
mutagenic and carcinogenic potencies of chemical carcin-
ogens, there are potent chemical carcinogens, such as
TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) that are not
mutagens even as judged by the most modern methods
available[11].
Furthermore, a thin film of apparently any smooth mate-
rial, introduced under the skin of a mouse, can induce a
sarcoma, but if the surface of the film were appropriately
roughened, tumor is not induced [12]. This phenomenon
suggests that a mere tissue disturbance, a disturbance that
is unlikely to be mutagenic, can induce neoplasia. This
notion is consonant with the purported roles of inflam-
mation [13] and of trauma [14] in the genesis of many
cancers. In chemical carcinogenesis, a recent study has
shown that the carcinogen need not even be applied
directly to the cells that undergo transformation. Thus,
application of the carcinogen to the stroma of the mam-
mary fat-pad in the rat could induce epithelial cancers in
untreated mammary cells that were subsequently exposed
to that previously treated stroma [15]; since the carcino-
gen had long since disappeared, a disturbed stromal-epi-
thelial interaction was apparently critical. Other
analogous experiments have been reviewed [15]
An early observation that called the mutation hypothesis
into some question was that when a carcinogen was
applied to a tissue or to a culture of supposedly normal
cells, persistent change could be observed in most or even
in all of the targets. Thus, for example, exposure of mouse
cells in culture to a carcinogenic chemical produced, in
100% of the cells, a change that made them hypersuscept-
able to transformation [16]. Furthermore, the cells
became resistant to the toxicity of the carcinogen
[5,17,18]. Mutation is usually thought of as a rather ran-
dom and sporadic process very different from a phenom-
enon in which virtually all target cells show the same
adaptive change.
A large number of analogous observations have been
reviewed [8]. These studies suggest that cancer may usu-
ally be initiated in a broad field of tissue that undergoes a
general adaptive change rather than being initiated by rare
mutational changes [5].
Perhaps the most persuasive observations suggesting that
some change other than mutation underlies the induction
of cancer are observations concerning regressions. If
regression occurs via a return of cancer cells to a normal
non-cancerous phenotype, it becomes difficult to argue
that the lesion had been the result of mutation. Clinically,
cancer regression is a well documented fact, albeit that it
occurs in a very small percentage of well-established clin-
ical cases. It is more common in childhood cancer, most
notably in neuroblastoma, but can be observed sporadi-
cally in a vast variety of neoplasms. Most of these regres-
sions are probably caused by a change to a more normal
phenotype, a differentiation rather than cell killing. This
process of differentiation seems clear in the case of neu-
roblastoma [19].
Painting the mouse skin with a chemical carcinogen can
result in numerous papillomas. Few of these progress to
become malignant; most regress. It has been shown in the
mouse-skin system that the regression can occur in the
probable absence of any anticancer immunity [20]. In the
analogous liver system, reversion of the initial lesions to a
more normal phenotype is well documented [5]. Regres-
sions are characteristic of only the initial papillomas; after
some progression of a lesion, if such occurs, regression of
that lesion becomes less common. Be it noted that it is
probable that many epithelial tumors in mammals, but
apparently not all [21], are preceded by small, benign,
focal hyperplasias, most of which do not progress and
many of which may regress.
Regression toward a normal phenotype has also been
demonstrated in some other experimental systems; most
notably, by the injection of embryonal carcinoma cells
into a developing blastocyst [22,23]. Hepatocarcinoma
cells have also been normalized in the environment of the
liver [24]. Similarly, melanoma was regulated by embry-
onic skin [25]. Recently, Hochedlinger et al. reported
reprograming of a melanoma genome by nuclear trans-
plantation into an enucleated egg [26]. A variety of other
methods have also been able to induce reprogramming
and differentiation in cancer cells [27,28].
It could be argued that, although in all these cases the can-
cer genes were able to produce an apparently normal phe-
notype, perhaps a mutated genome nonetheless
remained, its oncogenic potential nullified by still
unknown homeostatic devices. However, in the Illmensee
and Mintz experiment, it was reported that embryonal
carcinoma cells placed in the blastocyst sometimes gave
rise, within the resulting mouse, to germ cells of cancerCancer Cell International 2005, 5:9 http://www.cancerci.com/content/5/1/9
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origin which could be used to produce an apparently nor-
mal second generation mouse! The authors concluded
"that teratocarcinogenesis entails changes in gene func-
tion rather than gene structure" [23].
The new paradigm
The new paradigm that seeks to explain these various
studies has been most recently expounded by Soto and
Sonnenschein who call their version the TOFT or "tissue
organization field theory "[1]. The essence of the new par-
adigm is the concept that disturbances in cell to cell sign-
aling rather than mutation result in the heritable changes
in gene expression that are the cause of cancer. What fol-
lows is my own interpretation of the new paradigm stress-
ing possible reasons why some cancers, while probably
not caused by mutation, exhibit so many mutations.
(A).......Starting premise: Cancer is initiated by a loss of 
gene function
Soto and Sonnenschein [1] best articulated the fact that
the default condition in single-celled species and in cells
separated in tissue culture is not quiescence, but prolifer-
ation. Cells seem to proliferate unless inhibited by being
part of a multicellular organism. Thus, it follows that
when cells proliferate in a neoplasm, it is probably
because the natural inhibitors to cellular proliferation
found in multi-celled creatures are, for one reason or
another, defective. In the neoplasm, the normal inhibi-
tion to proliferation has been, to a large degree, removed.
Being impressed with the extent to which cancers and
embryos share characteristics, I am inclined to believe that
the critical genes that lose expression are often among
those whose function is to silence those genes that specify
embryonic development. The latter genes I will, for con-
venience, term ED for embryo development genes and the
former I will call SED for suppressors of embryo development
genes. It is in the silencing of SED genes that A. Knudsen's
two hit theory may be relevant [29]. Because the SED
genes are themselves naturally silenced in the embryo,
embryonic growth and development can proceed. As the
animal ages, various SED genes, that were unexpressed in
the embryo, gradually become expressed according to the
programmed schedule of embryogenesis. The genes spec-
ifying embryonic growth, the ED, are, thereby, gradually
silenced. When and if, at some later time in life and at
some particular site, the SED genes, because of some mal-
function, are again silenced, corresponding ED genes
might again be expressed. Such reexpression, now as
oncogenes, might lead locally to cellular proliferation and
possible neoplasia. Thus, a neoplasm could be considered
a post-embryonic, bizarre, local recapitulation of one or
more facets of embryogenesis caused by the pathologic
reexpression, in the post-embryonic animal, of normal
embryo development genes (ED).
If this thesis is correct, apparent "oncogenes" are probably
ED genes whose normal function, when expressed in the
embryonic animal, is to support embryonic development,
but if pathologically reexpressed in post-embryonic life
may result in neoplasia. Thus, meduloblastoma, a com-
mon brain tumor in childhood, is apparently dependent
upon the reactivation and perhaps actual amplification of
OTX2, a so-called oncogene that is an ED gene essential
for normal brain development, but whose expression is
ordinarily suppressed in later life [30]. Suppression of
OTX2  in meduloblastoma was apparently therapeutic
[30], just as in other studies, inactivation of the oncogene
MYC restored hepatocellular carcinoma to a normal phe-
notype [31]. Conversely, "tumor suppressor genes"
appear to be SED genes whose inactivation may promote
tumor growth by allowing greater expression of ED genes.
There is much evidence to show that among the bizarre
chromosomal abnormalities often seen in cancers, there
are some, such as particular translocations, that are asso-
ciated with a particular type of neoplasm. The best studied
of these may be the translocation that results in the Phila-
delphia chromosome and chronic myelogenous leuke-
mia. It is clear that the chromosomal breakpoints tend to
be associated with the expression of particular oncogenes
[32]. The new paradigm does not shed light upon whether
the oncogene expression precedes or follows the chromo-
somal breakage, but does suggest that some critical epige-
netic disruption in cell-to-cell signaling probably
antedated both.
(B)........DNA repair does not occur or is slow among 
silenced genes
There is experimental evidence for this phenomenon, at
least in a transgene [33]. It seems entirely reasonable that
an organism would not expend much energy to repair
unexpressed or silenced genes. Because of this normal lack
of DNA repair, I postulate that mutations will tend to
accumulate, at each cellular replication [34], among those
genes silenced during carcinogenesis; ie., mutations will
accumulate among silenced SED genes whose normal
function in the adult had been to inhibit the correspond-
ing ED genes that specify embryonic-type growth and
development. Thus, my interpretation of the new para-
digm suggests that most mutations in cancer are the result
of the lack of repair in silenced SED genes; the mutations,
for reasons to be explained shortly, are postulated to be,
at least in most cases, the result rather than the cause of
the silencing. Unrepaired mutations among unexpressed
genes might sometimes be numerous and might even sim-
ulate the action of a mutator phenotype without the
necessity of a mutation in any of the normal DNA repair
mechanisms. Mutations may also be common in unex-
pressed genes in normal adult cells, but these may remain
unnoticed unless revealed in a cancer.Cancer Cell International 2005, 5:9 http://www.cancerci.com/content/5/1/9
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One corollary is the prediction that some tumors may not,
in actuality, have many more mutations than does the
specific normal tissue of origin. There is a dearth of studies
actually comparing the mutation frequencies in tumors
with the frequencies in comparably treated but non-
tumorous parental tissues. However, the data in one
recent paper suggest that the frequency of mutations in
tumors may often be no greater than that in comparably
treated but non-tumorous tissues of the same type as that
in which the tumor had originated [35]. These data argue
against the etiological importance of most of the muta-
tions that occur in neoplasms and suggest, additionally,
that a mutator phenotype may not be common. However,
the postulated lack of DNA repair in silenced genes sug-
gests that when tumors, perhaps late in their progression,
do exhibit numerous mutations, these probably occurred
in previously silenced genes.
(C).........Mutations will eventually "hard wire" the silenced 
genes
The longer a cancer has been in existence and the larger
the lesion, the greater, presumably, will be the number of
mutations. The mutations are postulated to confirm and
solidify rather than cause the neoplastic state; these muta-
tions will tend to "hard wire" and make irreversible the
lack of expression in epigenetically silenced SED genes
within a tumor. Gene expression in neoplasia, at least in
Morris hepatomas, has indeed been observed to become
relatively fixed and unresponsive to environmental sig-
nals [36]. Although these apparently diploid hepatomas
were induced and selected to have the least change from
normal that a transformed cell could possibly have, "the
Morris hepatomas have a common tendency to be resist-
ant to various combinations of inductions and repres-
sions. Each line tends to be more or less frozen...."[37].
Probably, because of mutations in the newly silenced
genes, a neoplasm will, over time, become less and less
susceptible to any regression that might involve an epige-
netically-induced return to a more normal pattern of gene
expression.
This formulation offers a possible insight into the well
documented tendency of various types of aberrant
growths and neoplasms to undergo spontaneous regres-
sions in the infant and for malignancies in early child-
hood to be surprisingly amenable to treatment. It seems
reasonable to propose that the processes of embryonic
growth and development gradually subside as an infant
matures; presumably, this subsidence is caused by the
gradually increasing expression of SED genes which
would silence the expression of the ED genes upon which
normal development depends. Neoplasia, in my interpre-
tation of the new paradigm, is postulated to be dependent
upon the locally inappropriate and untimely expression
of ED genes consequent upon the silencing of their corre-
sponding SED genes. However, as the infant ages, the sup-
pressor genes (SED) are programed to gradually increase
their expression; gradually the inappropriately expressed
ED genes within the tumor might therefore be suppressed
and thus make a childhood neoplasm, such as a neurob-
lastoma [19], surprisingly likely to lose its neoplastic qual-
ities and undergo differentiation.
It has been observed that the newborn animal may be
more susceptible to chemical carcinogens than is the adult
[38]. Could this phenomenon also be related to the pos-
tulation that SED genes have not as yet, in the newborn,
become fully expressed and that their expression is conse-
quently more easily blocked by a carcinogen than would
be the case at a later age?
In a possibly related observation, it has been observed
that transplantation of the nucleus of a frog-kidney carci-
noma-cell into an enucleated frog egg commonly sup-
ported normal development through the swimming
tadpole stage [39]. No adult frogs were obtained. Appar-
ently, the ED genes of the cancer cell nucleus lacked muta-
tions that would have prevented embryonic development,
but the presumed "hardwired" changes (mutations) in the
silenced suppressor genes (SED) may have prevented the
transition to the normal adult condition of silenced and
unexpressed ED. In other words, the carcinoma nucleus
was competent for either embryo or tumor growth, but
was apparently incompetent for normal adult function-
ing, a set of facts that seems to fit perfectly with the thesis
I have been advancing.
Parenthetically, random mutations in silenced genes may
be the cause of the relative difficulty experienced in clon-
ing adult somatic cells for reproductive purposes; most of
the developmental genes (ED) in the adult cells would
have been silent for long periods of time and thus may
sometimes have acquired too many unrepaired muta-
tions.
(D)........The loss of expression among the genes that 
suppress developmental genes, is seldom caused by 
mutation
According to my interpretation of the new paradigm, the
loss of expression among SED genes is usually the result
of epigenetically-induced disruptions of normal cell to
cell signals. That the signaling disruptions are probably
not caused by mutation is inferred primarily by the previ-
ously noted tendency of early tumors to undergo regres-
sion via a return to a normal pattern of gene expression, a
phenomenon which would be more difficult to explain
were the disruptions mutational. The correct signals are
supposedly essential, in the adult, for ensuring transcrip-
tion in those genes (SED) that normally suppress develop-
mental genes (ED).Cancer Cell International 2005, 5:9 http://www.cancerci.com/content/5/1/9
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Objections to the new paradigm
A possible objection to the new paradigm is the fact that
there is much evidence that each cancer may often be
clonally derived from a single cell [3,40,41]. On its face,
this evidence suggests mutation. However, there are other
reasonable explanations for apparent clonality. The new
paradigm suggests that cancer supposedly originates via
adaptive epigenetic changes within a tissue; however, the
arisal of focal papillomas suggests that the adaptive
changes are not uniformly great among all the cells of that
tissue. Thus, some clones may achieve a competitive
advantage (based upon epigenetically-induced differen-
tial gene expression) and this competitive advantage
might eventually and erroneously simulate an origin from
a single cell. Supporting this hypothesis is the observation
that mouse skin papillomas induced by initiation-promo-
tion appear to be clonal while those induced by carcino-
gen alone are multiclonal [42] (unless induced by a very
small dosage of carcinogen [3]).
Conclusion
The new paradigm states that cancer is usually caused by
epigenetic disturbances that interfere with cell to cell sig-
naling. My own view of the new paradigm is that this
interference probably silences, in a stable and heritable
way, genes (SED) whose function, when expressed, had
been to repress various genes (ED) responsible for aspects
of embryonic development. A neoplasm is thus consid-
ered, in my formulation, to be caused by the local reex-
pression of normal embryonic genes (ED), genes that
should have been expressed only at an earlier time and/or
a different place.
I also propose that mutations tend to go unrepaired in
those genes already silenced by epigenetic mechanisms;
these mutations are postulated to accumulate without
phenotypic consequence. Silenced genes, both in normal
tissues and in tumors, presumably beget mutations, but
these, according to my interpretation of the new para-
digm, seldom play a significant role in the etiology of can-
cer. However, such mutations may act to "hard wire" the
silenced suppressor genes (SED); this may result in the
irreversible expression of embryonic genes (ED) which, in
a cancer, are called oncogenes and which drive cancer
development. This formulation explains why cancers tend
to become with time progressively less likely to regress
and progressively more difficult to treat.
Although my formulation of the new paradigm is indubi-
tably a simplistic view of a very complex process, it seems
congenial with present information and, I believe, may
actually reflect, to some extent, the true reality.
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